Comparison of the Continuous Glucose Monitoring Profiles of Four Glucose-Lowering Medications in the GRADE Randomized Trial - PubMed
5 hours ago
- #GRADE trial
- #continuous glucose monitoring
- #type 2 diabetes
- The study compared continuous glucose monitoring (CGM) metrics among four glucose-lowering medications (insulin glargine, glimepiride, liraglutide, sitagliptin) added to metformin in the GRADE trial.
- Sitagliptin and liraglutide groups showed the highest time in range (TIR70-180), lowest time below range (TBR<70), and lowest coefficient of variation (%CV).
- Glimepiride had the worst CGM profile, with the lowest TIR70-180, highest %CV and TBR<70, and the only daytime hypoglycemia events.
- Incretin-based drugs (liraglutide and sitagliptin) best achieved consensus goals, including very low TBR<54 and combined TIR70-180 >70% with TBR<70 <4%.
- CGM metrics provided clinical insights beyond HbA1c, guiding diabetes management by highlighting differences in glucose variability and hypoglycemia risk.